Pharmacokinetics and extrapulmonary $\beta_2$ adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers

B J Lipworth, D J Clark, P Koch, C Arbeeny

Abstract

**Background** – Racemic salbutamol remains one of the most commonly used bronchodilators in the treatment of reversible airways obstruction. Data from animal and human studies suggest that the S-isomer, whilst contributing no bronchodilator activity, may induce increased bronchial hyperreactivity and may explain the adverse effects of regular racemic salbutamol on asthmatic disease control. The purpose of this study was to evaluate the dose-response effects of racemic (+/-) salbutamol and its R(-) and S(+) isomers in terms of pharmacokinetics and pharmacodynamics at extrapulmonary $\beta_2$ adrenoceptors when given by the inhaled route to healthy volunteers.

**Methods** – Twelve healthy volunteers of mean age 20.6 years were studied in a double blind, placebo controlled, crossover design comparing cumulative doubling doses of nebulised R-salbutamol (R) and S-salbutamol (S) isomers (200 µg/400 µg/800 µg/1600 µg/3200 µg) and racemic salbutamol (RS) (400 µg/800 µg/1600 µg/3200 µg/6400 µg). Doses were administered at 20 minute intervals $(t_0/t_{20}/t_{40}/t_{60}/t_{80})$ and measurements were made of extrapulmonary $\beta_2$ responses as an increase in finger tremor and heart rate and fall in plasma potassium at baseline and each dose level $(t/t_{10}/t_{20}/t_{30}/t_{40}/t_{50}/t_{60})$. Plasma levels of salbutamol were measured at 15 minutes after each dose with a further sample at 30 minutes after the last dose $(t_{100})$.

**Results** – Pharmacodynamics showed dose related $\beta_2$ responses for R-salbutamol and RS-salbutamol but not for the S isomer, and a plateau in response was not reached within the administered dose range. No differences in responses were found between R-salbutamol and RS-salbutamol when compared on a 1:2 microgram basis. The effects of the S isomer were indistinguishable from those of placebo. For all $\beta_2$ responses there were differences between R-salbutamol and S-salbutamol (for $t_{100}$ response as change from placebo); tremor (log units): R 0.74 vs S 0.02 (95% CI 0.39 to 1.03); fall in potassium (mmol/l): R 0.35 vs S -0.02 (95% CI 0.03 to 0.71). Pharmacokinetics showed consistently higher levels for S-salbutamol than R-salbutamol at 15 minutes after each dose, with R-salbutamol already being cleared and S-salbutamol reaching peak levels at 30 minutes after the last dose $(t_{100})$.

There were higher plasma levels of R-salbutamol and S-salbutamol following administration of the respective isomers alone compared with their levels after administration of the racemate, suggesting an influence of each isomer on the clearance of the opposite isomer when given as a racemate.

**Conclusions** – The S-isomer of salbutamol has no detectable activity at extrapulmonary $\beta_2$ adrenoceptors whilst exhibiting higher plasma levels than the R-isomer, in keeping with greater clearance of R-salbutamol than S-salbutamol. Inhalation of R-salbutamol and RS-salbutamol produced dose-related $\beta_2$ responses which were equivalent when compared on a 1:2 microgram basis, despite higher plasma levels of R-salbutamol after administration of the R isomer than after administration of the racemate. Further dose ranging studies are required at steady state to evaluate the pharmacokinetics of R- and S-salbutamol and their relative effects on bronchial hyperreactivity when given on a regular basis to asthmatic subjects.

*Thorax* 1997;52:849–852

Keywords: salbutamol, nebulised, racemic, enantiomers, $\beta_2$ adrenoceptors, pharmacokinetics.

There has been considerable debate as to whether the use of regular $\beta_2$ agonist therapy is associated with increased morbidity and mortality in asthmatics.1 This continues to be relevant, despite a well established move towards earlier use of preventive treatment in view of the fact that large numbers of less stable asthmatic subjects continue to use high doses of regular $\beta_2$ agonists. Subsequent use of preventive treatment in view of the increased bronchoconstrictor stimuli such as histamine, methacholine, allergen, and adenosine monophosphate,2 whilst there is also a rebound increase in the histamine response after treatment with regular terbutaline.6 Also, perhaps more importantly, following regular use of in-
haled salbutamol there is an increase in both early and late airway responsiveness to allergen. Indeed, concomitant administration of inhaled corticosteroid does not appear to prevent the increased airway responsiveness to allergen induced by regular salbutamol.

The mechanism behind these changes in airway responsiveness has been the topic of much research. The agonist activity of racemic salbutamol is thought to reside solely with the R configuration. However, in sensitised guinea pigs the racemates and S isomers of isoprenaline, terbutaline, and salbutamol have been shown to induce airway hyperresponsiveness. The effects of racemic salbutamol and its constituent isomers, R-salbutamol and S-salbutamol, have been evaluated in asthmatic subjects. This revealed that the S isomer of salbutamol produced hyperresponsiveness to methacholine, whilst the R isomer reduced hyperresponsiveness more effectively when given alone than when administered as the racemate. However, these findings have been criticised in that the analysis was performed on non-transformed skewed data, as well as reporting the final dose of methacholine rather than the shift in PC_{20} value. We have evaluated for the first time the pharmacokinetics and dose-response effects of racemic (+/-) and the R (-) and S (+) isomers of inhaled salbutamol at extrapulmonary β2 adrenoceptors in man.

### Methods

#### SUBJECTS AND PROTOCOL

Twelve normal subjects of mean (SE) age 20.6 (0.40) years and forced expiratory volume in one second (FEV1) of 108.9 (2.1)% were studied in a double blind, crossover study to compare cumulative doubling doses of nebulised placebo, R-salbutamol and S-salbutamol (200 μg/400 μg/800 μg/1600 μg/3200 μg) and racemic (RS) salbutamol (400 μg/800 μg/1600 μg/3200 μg/6400 μg). All treatments were given via a System 22 Sidestream nebuliser (Medicaid, Pagham, UK) with a fill volume of 4 ml driven by compressed air at a flow rate of 8 l/min and nebulised to dryness. Doses were given at 20 minute intervals (t0/t20/t40/t60/t80). Measurements of extrapulmonary β2 responses were made over a five minute period at baseline and at 15 minutes after each dose administration corresponding to t0/t20/t40/t60/t80/t100 for each dose level. Samples were also taken for measurement of plasma salbutamol levels at 15 minutes after each dose administration, with an extra sample taken at 30 minutes after the last dose (t110). All measurements were made with the subject supine. The subjects were studied on four days, each separated by one week.

### MEASUREMENTS

Postural finger tremor was measured as previously described with an accelerometer transducer (Entran, Ealing, UK). Heart rate was measured from standard lead II of an electrocardiogram monitor. Plasma potassium levels were assayed by flame photometry using an IL943 analyser (Instrumentation Laboratory Ltd, Warrington, UK). The intra-assay and interassay values for analytical imprecision were 0.41% and 1.04%, respectively. The assay for determination of plasma levels of R- and S-salbutamol was made by high performance liquid chromatography with fluorescence detection and was fully validated according to published guidelines with a limit of quantitation of 0.25 ng/ml.

### STATISTICAL ANALYSIS

The results were analysed using the “Statgraphics” statistical software package (STSC

### Table 1 Mean (SE) baseline values (at t0) for extrapulmonary β2 responses

<table>
<thead>
<tr>
<th></th>
<th>RS-salbutamol</th>
<th>R-salbutamol</th>
<th>S-salbutamol</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tremor (log units)</td>
<td>0.366 (0.014)</td>
<td>0.379 (0.015)</td>
<td>0.397 (0.015)</td>
<td>0.377 (0.017)</td>
</tr>
<tr>
<td>Potassium (mmol/l)</td>
<td>4.47 (1.01)</td>
<td>4.45 (0.07)</td>
<td>4.33 (0.08)</td>
<td>4.15 (0.06)</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>67.7 (2.9)</td>
<td>64.4 (3.0)</td>
<td>63.8 (3.0)</td>
<td>63.5 (1.8)</td>
</tr>
</tbody>
</table>

There were no significant differences between the four treatments for any of the measured parameters.

### Table 2 Values for extrapulmonary β2 responses for R-salbutamol (R), S-salbutamol (S) and racemic salbutamol (RS) at each time point (20–100 minutes) and also for area under curve (AUC)

<table>
<thead>
<tr>
<th></th>
<th>20 min</th>
<th>40 min</th>
<th>60 min</th>
<th>80 min</th>
<th>100 min</th>
<th>AUC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tremor (log units)</td>
<td>0.24</td>
<td>0.37</td>
<td>0.45</td>
<td>0.61</td>
<td>0.66*</td>
<td>0.76*</td>
</tr>
<tr>
<td></td>
<td>(0.07)</td>
<td>(0.07)</td>
<td>(0.07)</td>
<td>(0.07)</td>
<td>(0.07)</td>
<td>(0.07)</td>
</tr>
<tr>
<td>R</td>
<td>0.04</td>
<td>0.39</td>
<td>0.39</td>
<td>0.57</td>
<td>0.74*</td>
<td>0.71*</td>
</tr>
<tr>
<td></td>
<td>(0.22)</td>
<td>(0.22)</td>
<td>(0.22)</td>
<td>(0.22)</td>
<td>(0.22)</td>
<td>(0.22)</td>
</tr>
<tr>
<td>S</td>
<td>-0.02</td>
<td>0.003</td>
<td>-0.04</td>
<td>-0.04</td>
<td>0.03</td>
<td>-0.03</td>
</tr>
<tr>
<td></td>
<td>(-0.15)</td>
<td>(-0.15)</td>
<td>(-0.15)</td>
<td>(-0.15)</td>
<td>(-0.15)</td>
<td>(-0.15)</td>
</tr>
<tr>
<td>Potassium (mmol/l)</td>
<td>-0.13</td>
<td>0.13</td>
<td>0.28</td>
<td>0.30</td>
<td>0.41*</td>
<td>0.42*</td>
</tr>
<tr>
<td></td>
<td>(0.22)</td>
<td>(0.22)</td>
<td>(0.22)</td>
<td>(0.22)</td>
<td>(0.22)</td>
<td>(0.22)</td>
</tr>
<tr>
<td>R</td>
<td>0.11</td>
<td>0.07</td>
<td>0.19</td>
<td>0.19</td>
<td>0.35*</td>
<td>0.30*</td>
</tr>
<tr>
<td></td>
<td>(0.16)</td>
<td>(0.16)</td>
<td>(0.16)</td>
<td>(0.16)</td>
<td>(0.16)</td>
<td>(0.16)</td>
</tr>
<tr>
<td>S</td>
<td>-0.04</td>
<td>-0.13</td>
<td>-0.06</td>
<td>-0.08</td>
<td>-0.02</td>
<td>-0.11</td>
</tr>
<tr>
<td></td>
<td>(-0.21)</td>
<td>(-0.21)</td>
<td>(-0.21)</td>
<td>(-0.21)</td>
<td>(-0.21)</td>
<td>(-0.21)</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>-0.5</td>
<td>5.9</td>
<td>10.2</td>
<td>9.7</td>
<td>10.5*</td>
<td>670*</td>
</tr>
<tr>
<td></td>
<td>(3.4)</td>
<td>(3.4)</td>
<td>(3.4)</td>
<td>(3.4)</td>
<td>(3.4)</td>
<td>(3.4)</td>
</tr>
<tr>
<td>R</td>
<td>-2.7</td>
<td>4.6</td>
<td>6.8</td>
<td>8.6</td>
<td>13.4*</td>
<td>600*</td>
</tr>
<tr>
<td></td>
<td>(7.2)</td>
<td>(7.2)</td>
<td>(7.2)</td>
<td>(7.2)</td>
<td>(7.2)</td>
<td>(7.2)</td>
</tr>
<tr>
<td>S</td>
<td>0.2</td>
<td>1.6</td>
<td>6.0</td>
<td>5.3</td>
<td>0.3</td>
<td>110*</td>
</tr>
<tr>
<td></td>
<td>(-6.1)</td>
<td>(-6.1)</td>
<td>(-6.1)</td>
<td>(-6.1)</td>
<td>(-6.1)</td>
<td>(-6.1)</td>
</tr>
</tbody>
</table>

Results are given as mean change from placebo with 95% CI for mean for t110 and AUC only.

Units for AUC: tremor (log units.h), potassium (mmol.h/l), heart rate (beats).

*p<0.05 versus placebo for t110 and AUC.
Pharmacokinetics of nebulised racemic salbutamol and its isomers

Data were calculated as area under the curve (AUC) in order to obviate multiple comparisons at each time point. For all parameters comparisons were made by multifactorial analysis of variance (MANOVA) and Duncan's multiple range testing was used to establish where the differences were significant for $t_{100}$ and AUC data only. A probability value of $p < 0.05$ (two tailed) was considered significant.

The study was designed with 80% power (beta error = 0.2) in order to detect a 20% difference in tremor between treatments.

Results

Extrapulmonary $\beta_2$ Responses

There were no differences in baseline values ($t_0$) between the four treatments (Table 1). A dose-response effect was observed for R-salbutamol and RS-salbutamol but not for S-salbutamol (Table 2, Fig 1). A plateau in the response was not reached within the administered dose range for R-salbutamol (3200 µg) or RS-salbutamol (6400 µg). No differences were found between R- and RS-salbutamol when compared on a 1:2 microgram basis. There were no differences between S-salbutamol and placebo. For all $\beta_2$ responses there were significant differences between R- and S-salbutamol isomers.

Pharmacokinetics

Plasma levels 15 minutes after administration of each dose were consistently higher for S-salbutamol than R-salbutamol (Fig 2). At 30 minutes after administration of the last dose ($t_{110}$) the plasma levels of R-salbutamol were beginning to fall, whilst levels of S-salbutamol reached their peak. Plasma levels of R- and S-salbutamol were higher following administration of the respective isomers alone than after administration of the racemate.

Discussion

The results of the present study show that S-salbutamol has no activity at extrapulmonary $\beta_2$ adrenoceptors whilst R-salbutamol and RS-salbutamol exhibit equivalent effects on a 1:2 microgram basis. It was noteworthy that plasma levels of S-salbutamol were consistently higher than R-salbutamol owing to greater clearance of the R isomer than the S isomer as was evident at 30 minutes after the last dose. Furthermore, higher plasma levels of R- and S-salbutamol occurred after administration of each isomer compared with levels after administration of the racemate, suggesting a possible influence of each isomer on the clearance of the opposite isomer when given as the racemate. The higher levels of R-salbutamol after administration of the R isomer alone compared with levels of R-salbutamol after administration of racemic salbutamol might partly explain previous observations of greater bronchoprotection with R-salbutamol than RS-salbutamol, although it would not explain the adverse effect of S-salbutamol alone on airway hyperreactivity.14 Our pharmacokinetic data are in keeping with...
The pharmacodynamic results are consistent with animal data that show the S-isomer to be devoid of activity at β2 adrenoceptors. This in turn suggests that any effects of the S-isomer on airway hyperreactivity must occur via a mechanism unrelated to β2 adrenoceptor occupancy. The aim of our study was to look at extrapolation of findings with salbutamol to stereoselective sulphate conjugation of salbutamol by human lung cytosol showing that the R-isomer is cleared 11 times faster than the S-isomer.17

This study was supported by a grant from Sepracor Inc (USA).

Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers.

B J Lipworth, D J Clark, P Koch and C Arbeeny

Thorax 1997 52: 849-852
doi: 10.1136/thx.52.10.849

Updated information and services can be found at:
http://thorax.bmj.com/content/52/10/849

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Drugs: respiratory system (526)
Asthma (1782)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/